Background and Purpose-Hematoma volume is the most potent predictor of outcome in spontaneous intracerebral hemorrhage (ICH), and hematoma expansion after hospital presentation occurs in up to 40% of individuals. Among patients with lobar ICH, the apolipoprotein E (APOE) ⑀2 allele predicts larger hematoma volumes at presentation. We investigated whether the ⑀2 allele also identifies individuals at increased risk of hematoma expansion. Methods-We analyzed 510 patients with primary ICH and genetic data available from an ongoing prospective cohort study.
A polipoprotein E (APOE) ⑀2 and ⑀4 alleles are independent risk factors for spontaneous intracerebral hemorrhage (ICH) in the lobar brain regions, 1 most likely a reflection of their role in cerebral amyloid angiopathy (CAA). 2, 3 Previous pathological studies have shown each allele's unique effect in CAA. The ⑀4 allele increases the severity of vascular amyloid deposition, whereas the ⑀2 allele appears to cause increased vasculopathic changes that lead to vessel rupture. 4, 5 Consistent with this, a multicenter genetic association study conducted by the International Stroke Genetics Consortium showed that larger ICH volume is associated with the APOE ⑀2, but not ⑀4, allele. As a result, APOE ⑀2 carriers are at disproportionately increased risk of mortality and poor outcome after ICH. 6 Hematoma expansion, or ongoing bleeding after initial presentation, is common in acute ICH with up to 40% of patients showing some degree of growth during hospital admission. [7] [8] [9] This expansion increases the risk of poor functional outcome and death. 10, 11 Therefore, attenuation of growth is an intriguing therapeutic strategy and the target of several clinical trials. 12, 13 Thus far, these clinical trials have not led to improved neurological outcome, perhaps because such therapies need to be targeted to the patients at highest risk for expansion to show any benefit. Challenges that remain, however, include the reliable identification of those patients at highest risk of subsequent hematoma expansion as well as a thorough understanding of the pathophysiologic mechanisms by which expansion occurs.
We therefore investigated whether possession of the APOE ⑀2 allele increases risk of hematoma expansion following lobar ICH. Furthermore, since not all lobar ICH is due to CAA, we hypothesized that the effect of APOE ⑀2 would be heightened in those with CAA-related ICH. To test these hypotheses, we performed a single-center prospective cohort study of patients with acute ICH.
Methods

Study Design
This is a retrospective analysis of data from an ongoing prospective cohort study performed at Massachusetts General Hospital, Boston, MA. The study was approved by the Institutional Review Board of Massachusetts General Hospital and written informed consent was obtained from all participants or their surrogates.
Patient Selection
Between January 1999 and December 2010 consecutive patients who presented with acute primary ICH 14 were screened and approached for participation in an ongoing genetic study of ICH. For the present analysis, we included patients meeting the following criteria: (1) Ն55 years (to minimize the possibility of inadvertently including patients with secondary ICH); (2) self-reported European or European-American ancestry; (3) diagnosis of nontraumatic ICH; (4) APOE genotyping available; and (5) a follow-up CT scan within 48 hours of the baseline CT. Exclusion criteria were defined as: presence of aneurysmal subarachnoid hemorrhage, trauma, brain tumor, hemorrhagic transformation of a cerebral infarct, vascular malformation, or any other known or suspected cause of secondary ICH. Cerebellar hemorrhages were excluded given differences in clinical course, including the routine performance of surgical decompression. (Figure 1) 
CAA-Related ICH
To determine the effect of APOE genotype on hematoma expansion in patients meeting criteria for CAA-related ICH, we separately analyzed possible and probable/definite CAA cases according to the Boston criteria. 15 Probable/definite CAA was defined as lobar ICH in the presence of confirmed CAA pathology and/or microbleeds confined to the lobar brain region. 16, 17 Possible CAA consisted of lobar ICH cases with available MRI scans lacking lobar microbleeds. A total of 114 (43%) lobar ICH cases had pathology and/or T2*, susceptibility, or gradient echo MRI data available for analysis. The presence and location of microbleeds were assessed using previously validated protocols. 15, 18 
Clinical Data
Patients (or their families or surrogates) were interviewed for age, sex, time of ictus, medical history, family history (including firstdegree relative with ICH), pre-ICH use of warfarin, antiplatelet therapy or statins, alcohol, and tobacco use. Hospital charts were reviewed for Glasgow Coma Scale score on arrival, mean arterial blood pressure, time to baseline imaging, and interscan time. Ninety-day modified Rankin Scale assessments were performed by telephone by trained study staff to assess functional outcome. 19 
CT Analysis
ICH location was assigned based on admission CT by study neurologists blinded to APOE genotype and clinical information. ICH exclusively involving the brain stem, thalamus, or basal ganglia was defined as deep or non-lobar ICH. ICH originating at the cortical-subcortical junction was defined as lobar ICH. Hemorrhages involving both territories were defined as mixed ICH and were excluded from analysis (nϭ16). Individuals with imaging of insufficient quality for location determination were also excluded from all analyses (nϭ16). Differences in ICH location were adjudicated by consensus.
Initial and follow-up ICH and intraventricular hemorrhage volumes were measured using Alice (PAREXEL International Corporation) and Analyze 9.0 (Mayo Clinic, Rochester, MN) software using previously described methods. 20, 21 Significant hematoma expansion was defined as an increase in ICH volume Ͼ6 mL or Ͼ33% from baseline ICH volume. 7, 9, 22 Genotyping DNA was isolated, quantified, and normalized to a concentration of 30 ng/L. Two single nucleotide polymorphisms of the APOE locus, rs7412 and rs429358, were independently genotyped using 2 separate assays. 17 The allelic reads from each assay were translated to APOE genotypes (⑀3⑀3, ⑀3⑀4, ⑀4⑀4, ⑀3⑀2, ⑀2⑀2, and ⑀2⑀4). Genotyping personnel were blinded to clinical and neuroimaging data. All ICH cases were in Hardy-Weinberg equilibrium for APOE genotypes.
Statistical Analysis
We tested for an association between the APOE ⑀2 and ⑀4 alleles and hematoma expansion analyzing deep and lobar ICH separately using logistic regression. Hematoma expansion was dichotomized (yes/no) for this analysis. Possible and probable/definite CAA-related ICH cases were also analyzed separately. Multivariate models included age, sex, hypertension, warfarin use, antiplatelet therapy, baseline ICH volume, intraventricular extension (yes/no), time to baseline scan, interscan time, number of ⑀2 alleles (0, 1, or 2), and number of ⑀4 alleles (0, 1, or 2).
Each patient's ICH expansion probability (ranging from 0% to 100%) was assigned using individual-level data and regression estimates from the results of logistic regression. These probability values were subsequently plotted (stratified by APOE genotype) to provide a qualitative estimate of the association between APOE variants and ICH expansion. In addition, we performed a time-toevent analysis using a Cox regression model. A probability value of Ͻ0.05 was considered statistically significant.
Results
Study Subjects
During the study period, a total of 1677 patients of Ն55 years presented with primary ICH. After applying clinical and radiological exclusion criteria and genotyping quality control, a total of 409 lobar ICH and 465 deep ICH cases remained. After selecting the cases with a follow-up CT available, a total of 265 lobar ICH and 245 deep ICH cases were available for analysis (Table 1 ). In addition, we created a table with the cohort characteristics for patients with lobar ICH stratified by APOE genotype (online-only Data Supplement Table I ; http://stroke.ahajournals.org). Patients without available follow-up CT more often used warfarin, had greater baseline ICH and intraventricular hemorrhage volumes, lower Glasgow Coma Scale scores, worse ninety-day modified Rankin Scale assessments and higher mortality rates (all PϽ0.05).
CT Images
The median time from last seen normal to baseline CT was . In deep ICH, median baseline hematoma volume was 12.6 mL (IQR, 1.9 -28.5) and median follow-up volume was 13.7 mL (IQR, 4.3-38.0). (Table 1) .
Hematoma Expansion
Lobar ICH Of 265 patients with lobar ICH, hematoma expansion was present in 39 (15%). To determine factors associated with hematoma expansion in lobar ICH, we first performed a univariate analysis (online-only Data Supplement Table II (Table 2 ). In addition, we performed a subgroup analysis of patients presenting within 6 hours of symptom onset (online-only Data Supplement Table III ). Figure 2 shows the predicted probability of lobar hematoma expansion stratified by APOE genotype. We found no evidence for an association between APOE ⑀4 and hematoma expansion (OR, 0.71; 95% CI, 0.30 -1.64; Pϭ0.42; Table 2 ).
To account for variation in time to repeat CT, and hence time to detection of expansion, we performed a time-to-event analysis. Both APOE ⑀2 (hazard ratio, 2.26; 95% CI, 1.30 -4.00; Pϭ0.005) and warfarin (hazard ratio, 3.21; 95% CI, 1.11-9.27; Pϭ0.031) remained independent predictors of hematoma expansion in lobar ICH after adjusting for potential confounders. (Table 3 ). Figure 3 shows the predicted probability of hematoma expansion stratified by APOE genotype and CAA diagnosis. 
Discussion
Our results demonstrate that patients Ͼ55 years of age with lobar ICH who carry the APOE ⑀2 allele are at an increased risk of hematoma expansion. This effect is particularly pronounced in patients meeting criteria for probable or definite CAA-related ICH. There was no effect of APOE ⑀2 on hematoma expansion in deep ICH and APOE ⑀4 had no effect on hematoma expansion in lobar or deep ICH. Consistent with the results of prior studies, 9,23 use of warfarin also predicted subsequent hematoma expansion regardless of hemorrhage location or CAA diagnosis.
The isolated effect of the APOE ⑀2 allele on hematoma expansion is in line with the results of previous studies, which suggest separate effects of ⑀2 and ⑀4 on vasculopathic CAA vessels. In these histopathologic series, it appears that the ⑀4 allele increases the severity of vascular amyloid deposition, whereas the ⑀2 allele appears to cause vasculopathic changes that are presumably more directly tied to vessel rupture. 4, 5 Consistent with this finding, the International Stroke Genetics Consortium recently reported the association between APOE ⑀2 and larger hematoma volumes in patients with lobar ICH, an effect not seen for APOE ⑀4, supporting the hypothesis that the APOE ⑀2 allele plays a unique role in the severity of vasculopathic changes in CAA. 6 The association between APOE ⑀2 and hematoma expansion is consistent with a model in which an initial ruptured vessel leads to cascading injury of nearby diseased small vessels. 24 Patients with increased severity of vascular amyloid without extensive secondary vessel wall breakdown (as might be expected in APOE ⑀4 carriers) appear at no higher risk of expansion, whereas those in whom the vascular walls have greater breakdown are at higher risk. Such patients (those with the APOE ⑀2 allele) are more likely to have a severely damaged vessel near the rupture site, which might then rupture in response to injury and lead to more additional bleeding. The fact that increased copies of the ⑀2 allele increase risk is consistent with this model. However, hematoma expansion occurring late in the course of disease might suggest that other mechanisms are also playing a role in the pathophysiology of hematoma expansion.
In previous work we noted differential effects of APOE ⑀2 and ⑀4 in relation to initial ICH volume, which may well reflect the same process; an initial rupture would normally be contained in a small space unless there is an adequately damaged vessel nearby to rupture itself in response to injury. 6 This raises the intriguing possibility of a threshold effect of amyloid-related vessel breakdown, whereby a small hematoma requires a sufficiently diseased nearby vessel to expand, although further studies are necessary to confirm this.
There is an urgent need for biomarkers that can be used to select patients and guide interventions that restrict hematoma expansion. 25 To date, clinical trials aimed at restricting expansion have not led to improved neurological outcome 12, 13 ; it may be necessary to target patients at highest risk for expansion to show benefit. One radiographic finding, the CT angiography "spot sign," has proven to be the strongest predictor of hematoma expansion and clinical outcome in patients with primary ICH. 20 -22,26 It may be that APOE genotype, or other markers of underlying vascular disease, can provide additional biomarkers with which to improve prediction in the acute setting.
This study is limited by its size, lack of replication, and the fact that follow-up CT scans were not performed with standardized timing. Thus, it is important to note that our ability to identify the precise time course over which expansion occurs is limited. This is a fundamental shortcoming for observational studies, in which CT timing is dependent on the clinical care providers. Furthermore, follow-up CT scans were disproportionately not available for those with the largest hematomas and early death. Although not replicated, our findings are consistent with previous research investigating the relationship between APOE and ICH. A last potential 
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limitation of our study is the use of the Boston criteria to classify possible, probable, and definite CAA-related ICH.
Because not all patients had pathology available (from either postmortem examination or cortical biopsy), this classification was partly based on MRI findings only. Overall, this hypothesis-generating analysis raises intriguing questions regarding the pathophysiology of hematoma expansion, which warrant further investigations.
In conclusion, we demonstrate that the APOE ⑀2 allele is associated with hematoma expansion in patients with lobar ICH. This effect is particularly prominent in the subset of patients who meet criteria for probable/definite CAA. Although future studies are required to replicate these results, our findings are consistent with the accumulating body of data on the role of APOE genotype in ICH. 
